ARRY-403, also known as AMG-151, is an orally available allosteric glucokinase (GK) activator developed for the treatment of type 2 diabetes mellitus (T2DM). ARRY-403 has many favorable physicochemical characteristics and ADME properties (low potential to cause drug–drug interactions (DDIs). ARRY-403 potently activates human glucokinase (GK) in vitro (EC50 = 79 nM at 5 mM glucose), with an S0.5 = 0.93 mM glucose (ARRY-403 at 5 mM) and Vmax = 134% compared to the no activator control. It possesses good in vitro drug-like properties (aqueous solubility, cell permeability, low low potential for drug-drug interactions, low predicted hepatic clearance), and selectivity against broad panels of receptors and enzymes.
CDMG1 is a novel Wnt inhibitor, promoting heart regeneration, injury repair, and myocardial hyperplasia through expansion of the cardiac progenitor cell population
MMG-11 inhibits both TLR2 1 and TLR2 6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2 1 and 5.7 μM for Pam2CSK4-induced hTLR2 6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.
Gel filtration medium G-100, a substance designed for protein purification, enables the separation and purification of proteins through gel filtration.